Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several
Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several products,including agents for imaging disease states such as deep veinthrombosis, pulmonary emboli, tumors and atherosclerotic plaque.Diatech said the patent puts it in a strong proprietary positionas it works to commercialize the agents.
The company also announced this month that it has receiveda $100,000 grant from the Heart and Lung Blood Institute divisionof the National Institutes of Health to research a potential newtherapeutic agent for the treatment of blood clots.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.